Source: The Life Sciences Report (08/03/2016)
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.
read more >
Source: The Life Sciences Report (07/20/2016)
Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy.
read more >
Source: Tracy Salcedo of The Life Sciences Report (07/13/2016)
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative.
read more >
Source: Tracy Salcedo of The Life Sciences Report (06/29/2016)
Given the uncertainty and dire economic forecasts following the Brexit vote,
The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry.
read more >
